Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-02-24Clinical Trial Update: Cryopreserved MMUD BM With PTCy for Hematologic Malignancies [Phase 1]
Phase 1 trial of cryopreserved MMUD bone marrow with post-transplant cyclophosphamide for hematologic malignancies has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2026-02-12Clinical Trial Update: Expanded Access to ABBV-787
Expanded access to ABBV-787 for Acute myeloid leukemia has been terminated. It is no longer available.
-
CLINICAL_TRIALS withdrawal · 2025-11-10Clinical Trial Update: A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies [Phase 1]
A Phase 1 study of Dual-Signaling Protein 107 (DSP107) in hematologic malignancies has been terminated, including studies in Acute Myeloid L…
-
CLINICAL_TRIALS withdrawal · 2025-10-10Clinical Trial Update: HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) [Phase 1]
A Phase 1 trial investigating HDM201 in combination with MBG453 or venetoclax in patients with acute myeloid leukemia or high-risk myelodysp…
-
CLINICAL_TRIALS withdrawal · 2025-07-14Clinical Trial Update: TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant [NA]
A clinical trial evaluating TCRαβ/CD19-depleted stem cell grafts for transplantation has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-07-03Clinical Trial Update: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL [Phase 1]
The Phase 1 study of BMF-219, Biomea Fusion's covalent menin inhibitor, in adults with AML, ALL, DLBCL, multiple myeloma, and CLL/SLL has be…
-
CLINICAL_TRIALS withdrawal · 2025-06-22Clinical Trial Update: A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias [Phase 1]
A Phase 1 trial of JNJ-75276617 in combination with conventional chemotherapy for pediatric and young adult patients with relapsed/refractor…
-
CLINICAL_TRIALS withdrawal · 2025-06-11Clinical Trial Update: Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia [Phase 1]
A Phase 1 clinical trial evaluating dual CD33/CLL1 CAR T cells for patients with refractory or relapsed Acute Myeloid Leukemia has been with…
-
CLINICAL_TRIALS withdrawal · 2025-06-03Clinical Trial Update: Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy [Phase 2]
Phase 2 trial evaluating Vyxeos (daunorubicin/cytarabine liposome) plus venetoclax versus azacitidine plus venetoclax in acute myeloid leuke…
-
CLINICAL_TRIALS withdrawal · 2025-05-30Clinical Trial Update: Efficacy of Decitabine in Clearance of MRD [Phase 1, Phase 2]
A phase 1/2 trial evaluating decitabine for clearance of minimal residual disease in acute myeloid leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-05-25Clinical Trial Update: Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor [Phase 1]
A Phase 1 study evaluating multi-antigen specific CD8+ T cells with decitabine and lymphodepleting chemotherapy for relapsed or refractory a…
-
CLINICAL_TRIALS withdrawal · 2025-05-01Clinical Trial Update: Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation [Phase 1]
Phase 1 trial evaluating dasatinib in combination with chemotherapy for relapsed acute myeloid leukemia with t(8;21) translocation and KIT D…
-
CLINICAL_TRIALS withdrawal · 2025-04-29Clinical Trial Update: Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study [NA]
A clinical trial testing a mobile intervention to improve adherence to oral anti-cancer medications in acute myeloid leukemia has been withd…
-
CLINICAL_TRIALS withdrawal · 2025-04-22Clinical Trial Update: Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction [Phase 2]
Phase 2 frontline trial evaluating cladribine/low-dose cytarabine alternating with decitabine versus hypomethylating agents plus venetoclax …
-
CLINICAL_TRIALS withdrawal · 2025-03-24Clinical Trial Update: DEC-C and Thioguanine for R/R AML [Phase 2]
A Phase 2 clinical trial evaluating DEC-C (decitabine/cedazuridine) and Thioguanine for relapsed/refractory acute myeloid leukemia has been …
-
CLINICAL_TRIALS withdrawal · 2025-03-12Clinical Trial Update: A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia [Phase 1, Phase 2]
A Phase 1B/2A trial evaluating the combination of ASTX727 with ASTX029 for Acute Myeloid Leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-01-29Clinical Trial Update: Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
A clinical trial investigating correlations between serum biomarkers and GVHD-related endothelial damage has been withdrawn. The study recor…
-
CLINICAL_TRIALS withdrawal · 2024-12-05Clinical Trial Update: Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT [Phase 1]
A Phase 1 trial evaluating a preemptive infusion of donor lymphocytes depleted of TCR+ T cells and CD19+ B cells after autologous stem cell …
-
CLINICAL_TRIALS withdrawal · 2024-11-25Clinical Trial Update: Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
A Travera Inc clinical trial (NCT04985357) evaluating mass response as a biomarker for tumor sensitivity to drugs has been withdrawn; no res…
-
CLINICAL_TRIALS withdrawal · 2024-11-14Clinical Trial Update: Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
The Phase 1 safety and efficacy study of CI-135 CAR-T cells for relapsed or refractory acute myeloid leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-10-01Clinical Trial Update: Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia [Phase 1, Phase 2]
A phase 1/2 clinical trial of induction therapy for FLT3-mutated acute myeloid leukemia has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS [Phase 1]
A Phase 1 trial of magrolimab in combination with azacitidine after allogeneic hematopoietic cell transplantation in high-risk acute myeloid…
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) [Phase 2]
A Phase 2 clinical trial evaluating CPI-613 (devimistat) in combination with metformin for relapsed or refractory acute myeloid leukemia has…
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]
The clinical trial studying ZN-d5 and ZN-c3 in acute myeloid leukemia was terminated; no results are provided in the update.
-
CLINICAL_TRIALS withdrawal · 2024-09-19Clinical Trial Update: Tislelizumab with Azacitidine in the Treatment of R/R AML [Phase 1, Phase 2]
This clinical trial update notes the phase 1/2 study of tislelizumab with azacitidine for refractory or relapsed acute myeloid leukemia has …